




The relative strengths and weaknesses of Bellerophon Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Bellerophon Therapeutics Inc compared to the market average is the variable Selling, General and Administrative Expense, increasing the Economic Capital Ratio by 5.8% points. The greatest weakness of Bellerophon Therapeutics Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 77% points.

The company's Economic Capital Ratio, given in the ranking table, is 115%, being 136% points below the market average of 252%.

Input Variable	Value in 1000 USD
Assets, Current	35,580
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	7,079
Liabilities, Non-Current	0
Other Assets	204
Other Compr. Net Income	-4.0
Other Expenses	30,403
Other Liabilities	32,325
Other Net Income	184
Other Revenues	0
Property and Equipment	1,026
Research and Development	17,854
Selling, General and Administrative Expense	6,745

Output Variable	Value in 1000 USD
Assets	36,810
Liabilities	39,404
Expenses	55,002
Revenues	0
Stockholders Equity	-2,594
Net Income	-54,818
Comprehensive Net Income	-54,820
BaseVar	65,702
ECR before LimitedLiability	-159%
Economic Capital Ratio	115%